The main aim of the present study was to investigate effects of partial reductions of electromyogram (EMG) on high-frequency scalp electroencephalogram (EEG) at rest and during performance of certain cognitive tasks. Nineteen healthy women performed the same cognitive tasks before and after cosmetic injections of Dysport in certain sites of facial muscles. Scalp EEG and EMG were recorded. Impact of Dysport injections on changes of spectral power in β2 and low γ frequency ranges (18-40 Hz) in EEG and EMG derivations was investigated. Also changes of spectral power in EEG and EMG derivations during comparisons of different cognitive states were calculated before and after Dysport injections separately. Dysport injections led to EMG decreases in facial muscles around the injection zones and also led to reductions of power of electric processes in scalp derivations. Along with it results of EEG power comparisons between the pairs of the cognitive states were qualitatively similar before and after Dysport injections. These facts to all appearance demonstrate that though scalp EEGs in the range above 15-40 Hz are contaminated by EMG, in certain experimental situations EMG contamination does not preclude qualitative detections of electroencephalographic correlates of mental activities in β2 and low γ frequency ranges. Parallel EEG and EMG registrations can help not to overestimate EMG contamination in psychophysiological EEG studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00221-016-4708-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of Relatox, a type of botulinum toxin, in treating focal spasticity of the upper limb caused by cerebrovascular accidents or traumatic brain injuries.
- It involved 210 patients divided into two groups; one received Relatox injections, while the other received Dysport. Both groups showed a reduction in spasticity over 12 weeks, with no significant differences between the two treatments.
- Various measurements were used to assess spasticity, disability, pain, and treatment satisfaction, and both medications were found to be effective, with a report on adverse events collected throughout the study.
[Investigation of general toxic effects of Relatox in comparison with Dysport].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
OOO NBC «Pharmbiomed», Moscow, Russia.
Objective: To evaluate the toxic effects of the agent Relatox on mature outbred rats and mice in an acute experiment in comparison with the registered analogue Dysport.
Material And Methods: Based on the aim of experiment, the acute toxic effects of Relatox and Dysport were assessed on two animal species: rats and mice at intraperitoneal and intramuscular administration at dose levels that made it possible to calculate the toxicological parameter values (initially 10-150 U/kg with subsequent usage of additional doses 20 U/kg to 300 U/kg depending on the agent and route of administration). The LD values and other acute toxic parameters were calculated using probit analysis.
Treatment with OnabotulinumtoxinA for Oromandibular Dystonia: A Systematic Review and Meta-Analysis.
Toxins (Basel)
December 2024
Department of Neurology, Tokushima University, Tokushima 770-8503, Japan.
Article Synopsis
- Oromandibular dystonia (OMD) is a condition causing muscle contractions in the jaw and related areas, and this study analyzed the effects of botulinum toxin (onabotulinumtoxinA) as a treatment.
- A meta-analysis of 26 studies with 1103 patients showed that 96.2% experienced a positive response to the injections, with 88.9% achieving significant improvement of over 50%.
- Although 17.8% of patients had adverse effects, mainly dysphagia (10.1%), the overall findings suggest that botulinum toxin is an effective treatment for OMD but further studies are needed for more conclusive results.
The Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial.
Toxins (Basel)
November 2024
Alfred Health, Melbourne, VIC 3004, Australia.
Article Synopsis
- This study analyzed the effects of botulinum toxin-A on upper limb issues in chronic stroke survivors, focusing on those with significant spasticity.
- The research involved 71 stroke survivors and measured changes in various outcomes, including upper limb activity, spasticity, and grip strength, before and three months after treatment.
- Results showed no significant improvement in any of the measured outcomes, indicating that botulinum toxin-A may not be beneficial for improving upper limb function in this patient group with severe activity limitations.
Stable Convergent Polyneuronal Innervation and Altered Synapse Elimination in Muscles from Patients with Blepharospasm Responding Poorly to Recurrent Botulinum Type-A Neurotoxin Injections.
Toxins (Basel)
November 2024
Institut des Neurosciences Paris-Saclay, UMR 9197, CNRS/Université Paris-Sud, 91198 Gif-sur-Yvette, Cedex, France.
Botulinum neurotoxin type-A (BoNT/A), which blocks quantal acetylcholine (ACh) release at the neuromuscular junction (NMJ), has demonstrated its efficacy in the symptomatic treatment of blepharospasm. In 3.89% of patients treated for blepharospasm at Tenon Hospital, BoNT/A was no longer effective in relieving the patient's symptoms, and a partial upper myectomy of the muscle was performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!